Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels

Abstract

The present invention relates to a use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.

1 . Use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor. 
     
     
         2 . The use according to  claim 1 , wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis. 
     
     
         3 . The use according to  claim 1 , wherein the type-2 dopaminergic receptor agonist is cabergoline. 
     
     
         4 . Use of cabergoline in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor. 
     
     
         5 . Cabergoline for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor. 
     
     
         6 . Cabergoline for use according to  claim 5 , wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis. 
     
     
         7 . A pharmaceutical composition comprising cabergoline as an active ingredient for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor. 
     
     
         8 . The composition according to  claim 7 , for use, wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis. 
     
     
         9 . The composition according to  claim 7  for oral administration.